Fig. 3
From: Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)
![Fig. 3](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12967-022-03592-4/MediaObjects/12967_2022_3592_Fig3_HTML.jpg)
Confirmed tumor response on whole body 18F-FDG PET/CT MIP images obtained in a66 year old male stage IV-M1c melanoma patient with a BRAF N486_P590del (in-frame deletion, class II BRAF mutation) treated with trametinib 2 mg QD plus dabrafenib 50 mg BID